Very Late Stent Thrombosis in a Drug-Eluting Stent due to Interruption of Anti-Platelet Agents in Patients With Acute Myocardial Infarction and Thrombocytosis by Choi, Hong Sang et al.
417
Print ISSN 1738-5520 / On-line ISSN 1738-5555
Copyright © 2011 The Korean Society of Cardiology
CASE REPORT
DOI 10.4070/kcj.2011.41.7.417
Open Access
Very Late Stent Thrombosis in a Drug-Eluting Stent  
due to Interruption of Anti-Platelet Agents in Patients  
With Acute Myocardial Infarction and Thrombocytosis
Hong Sang Choi, MD, Myung Ho Jeong, MD, Il Kook Seo, MD, Min Goo Lee, MD, Jum Suk Ko, MD, Keun Ho Park, MD, 
Doo Sun Sim, MD, Nam Sik Yoon, MD, Kye Hun Kim, MD, Hyung Wook Park, MD, Young Joon Hong, MD,  
Ju Han Kim, MD, Youngkeun Ahn, MD, Jeong Gwan Cho, MD, Jong Chun Park, MD, and Jung Chaee Kang, MD
The Heart Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University,  
Gwangju, Korea
ABSTRACT
Stent thrombosis is a fatal complication in patients who have undergone percutaneous coronary intervention, and discon-
tinuation of anti-platelet agent is a major risk factor of stent thrombosis. We report a rare case of very late stent thrombosis 
(VLST) following discontinuation of anti-platelet agents in a patient who experienced acute myocardial infarction and es-
sential thrombocytosis. She had undergone implantation of a drug eluting stent (DES) and a bare metal stent (BMS) two 
and half years prior to her presentation. VLST developed in DES, not in BMS, following interruption of anti-platelet therapy. 
(Korean Circ J 2011;41:417-420)
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 Introduction
Drug-eluting coronary artery stents (DES) are currently 
being widely used. The advantage of DES is that it markedly 
reduces the rate of restenosis and the need for repeat revas-
cularization.
1-3) Despite these promising advances, stent th-
rombosis appears to occur more frequently with DES. There-
fore, in patients with implanted DES, longer duration of anti-
platelet therapy is needed, and they should maintain anti-pla-
telet therapy even when they undergo endoscopic procedures. 
We report a case of very late stent thrombosis (VLST) that 
occurred only in DES, not in bare metal stent (BMS), follow-
ing discontinuation of anti-platelet therapy, in a patient present-
ed with essential thrombocytosis (ET) and acute myocardial 
infarction.
 
 Case
A 65-year-old female was transferred to the emergency de-
partment at our hospital, complaining of stabbing chest pain 
that radiated to her left arm and back that persisted over four 
hours. She had a history of acute ST-elevation myocardial in-
farction and underwent BMS implantation (4.0×25 mm and 
4.0×13 mm Coroflex Blue Stent) for the proximal and middle 
right coronary artery (RCA), respectively, as well as DES (a 
3.0×18 mm Cypher stent) implantation for the distal left cir-
cumflex artery (LCX) two-and-half years previously (Fig. 1). 
She had since commenced on dual anti-platelet therapy (as-
pirin 100 mg, clopidogrel 75 mg daily). Coronary angiography 
(CAG) performed after eight months showed no evidence of 
restenosis. She ceased taking aspirin and clopidogrel for an en-
doscopic procedure two days before her latest presentation.
On examination, she appeared to be in acute distress. Her 
blood pressure was 110/60 mmHg, her heart rate was 60 beat 
per minute, her respiratory rate was 16/min, and her temper-
ature was 37°C. Her oxygen saturation was 97% on room air. 
Pertinent findings on chest examination included fine crack-418   Late Stent Thrombosis in DES
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Fig. 1. Patient underwent percutaneous coronary intervention (PCI) in the right coronary artery (RCA) due to inferior ST elevation myocardial 
infarction two and a half years ago. Initial coronary angiogram revealed critical stenosis in middle RCA (95%) and distal left circumflex ar-
tery (LCX) (80%) (A and C). We deployed bare metal stent in the proximal and middle RCA (B), and drug-eluting stent in the distal LCX by 
staged PCI (D).
Fig. 2. Electrocardiogram showed ST-segment elevation in lead II, III and aVF.Hong Sang Choi, et al.   419
les heard at the bases. Her cardiovascular examination reveal-
ed normal first and second heart sounds, with no evidence of 
jugular venous distention, murmurs, rubs, or gallops. The re-
mainder of her physical examination was unremarkable.
Electrocardiogram showed ST-segment elevation in lead II, 
III and aVF (Fig. 2), and cardiac enzymes were within the nor-
mal limits (creatine kinase-MB 3.9 U/L, troponin-I 0.04 ng/
mL). Complete blood count (CBC) results were as follows: he-
moglobin level was 17.5 g/dL, hematocrit was 52.8%, and pla-
telet count was 1,168×10
3/mm
3. She underwent emergent 
CAG, which demonstrated thrombotic total occlusion of the 
distal LCX secondary to stent thrombosis, but the RCA stent 
was patent (Fig. 3). Therefore, we performed emergent PCI 
using 3.0 mm balloon for the distal LCX, and applied intraco-
ronary abciximab (Clotinab
®) for thrombi visualization. Post-
PCI CAG showed no residual stenosis and relatively good 
distal flow (Fig. 4).
During the patient’s hospitalization, we performed bone 
marrow biopsy to further evaluate the cause of thrombocyto-
sis, which confirmed ET. She was subsequently managed with 
repeated phlebotomy and platleletapharesis to reduce the level 
of hematocrit and platelet count. In addition, she was com-
menced with anagrelide and hydroxyurea, but her CBC pro-
file fluctuated during hospital stay. She subsequently made an 
uneventful recovery, and was discharged with continuous tri-
ple anti-platelet agent therapy of aspirin, clopidogrel and cilo-
stazol. After discharge, the patient has been followed up at the 
outpatient cardiology and hematology clinics without expe-
riencing further symptoms.
Discussion
We report this case to raise the awareness of coronary stent 
thrombosis associated with anti-platelet therapy discontinu-
ation. This case is very interesting in that the difference be-
tween DES and BMS, or essential thrombosis which might 
contribute to the development of VLST.
VLST is defined as stent thrombosis presented one year 
after PCI. Recently, some concerns have been raised that late 
or VLST tends to be more common in DES than BMS.
4-8) In 
this case, VLST has occurred in DES only, but not in a BMS. 
Similarly, Kim et al.
9) reported a case of VLST solely in DES, 
not in BMS. Some clinical data demonstrated that neointimal 
coverage after DES implantation was later than that in BMS.
10)11) 
Therefore, we hypothesized that the uncovered strut of DES 
persisted and stent thrombosis might have occurred under 
special circumstances, such as discontinuation of anti-plate-
let agents.
Fig. 3. Emergent coronary angiogram showed thrombotic total occlusion of the distal left circumflex artery due to drug-eluting stent thrombosis 
(A), and patent right coronary artery bare metal stent (B).
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Fig. 4. Coronary angiogram after balloon dilatation showed no re-
sidual stenosis and relatively good distal flow.420   Late Stent Thrombosis in DES
The role of anti-platelet therapy discontinuation in early st-
ent thrombosis is well-recognized,
12-14) but its role in LST and 
VLST remains unclear. However, current guidelines on anti-
platelet and anticoagulant therapy in endoscopic procedu-
res
15)16) recommend continuation of aspirin regardless of ble-
eding risk, and continuation of clopidogrel in low risk proce-
dures. On the contrary, the guidelines recommended stopp-
ing clopidogrel 7 days before a high risk procedure if the pa-
tient is at least 12 months post-DES insertion, and at least 1 
month post-BMS insertion. As such, our patient would have 
benefited from uninterrupted aspirin administration.
ET is a myeloproliferative disorder characterized by clonal 
proliferation of megakaryocytes, resulting in thrombocytosis. 
Thrombosis and hemorrhage are typical complications in 
patients with ET. Tefferi et al.
17) reported that major throm-
botic complications, such as cerebral ischemic attack and ac-
ute coronary syndrome, occurred in 7% of ET patients. Cases 
of acute coronary syndrome with ET were reported by some 
authors,
18-20) but our experience of VLST associated with ET 
was unique.
In conclusion, ET and discontinuation of antiplatelet ag-
ent might have contributed to VLST of the DES in our pa-
tient. Discontinuation of antiplatelet therapy, even after one 
year in patients who have undergone DES placement, requ-
ires extreme caution, particularly in patients with thrombo-
sis and acute coronary syndrome.
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